Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara
Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...
The Pharma Letter1h
Sandoz launches biosimilar Pyzchiva in USA
Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, ...
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...
Le Lézard6h
IPLOOK's Evolution Plan: Seamlessly Transitioning from 2G/3G to 4G/5G
As telecom operators face mounting pressure to modernize aging infrastructure while maintaining service continuity, IPLOOK delivers a cost-efficient evolution blueprint that bridges legacy 2G/3G ...
Sandoz launches biosimilar Pyzchiva in U.S. for all approved Stelara indications
Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the ...
Le Lézard7h
Market Dojo Introduce Transformative Sourcing, Intake and Orchestration with Focal Point
Market Dojo, a leader in eSourcing solutions, has partnered with Focal Point, a pioneer in intake and orchestration, to deliver an integrated platform that streamlines procurement success. A Seamless ...
kedglobal5h
Samsung lowers bar for hiring foreign talent in South Korea
South Korea’s biggest business group Samsung has sweetened the pot to win a technology talent war by lowering the bar for new ...